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The clinical experience recently reported with epidermal growth factor receptor (EGFR)-targeting drugs confirms the synergistic
interactions observed between these compounds and conventional cytotoxic agents, which were previously established at the
preclinical stage. There are, however, examples of major gaps between the bench and the bedside. Particularly demonstrative is the
failure of the tyrosine kinase inhibitors (TKIs) (gefitinib and erlotinib) combined with chemotherapy in pretreated nonsmall cell lung
cancer patients. These discrepancies can be due to several factors such as the methodology used to evaluate TKI plus cytotoxic agent
combinations in preclinical models and the insufficient consideration given to the importance of the drug sequences for the tested
combinations. Recent advances in understanding the biologic basis of acquired resistance to these agents have great potential to
improve their clinical effectiveness. The purpose of this review is to critically examine the experimental conditions of the preclinical
background for anti-EGFR drug–cytotoxic agent combinations and to attempt to explain the gap between clinical observations and
preclinical data.
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The epidermal growth factor receptor (EGFR) is present in many
cell types and can be considered as one of the best-characterised
ligand-receptor systems (Mendelsohn and Baselga, 2006). Epider-
mal growth factor receptor is a 170-kDa cell surface glycoprotein
containing three well-identified domains: an extracellular ligand-
binding domain, a hydrophobic membrane-spanning domain and
a cytoplasmic portion containing the tyrosine kinase activity. The
hyperactivation of EGFR signalling in tumours occurs via
independent or combined mechanisms: overexpression of the
receptor itself, autocrine overproduction of ligand with mainly
EGF and tumour growth factor (TGFa), and EGFR mutations,
notably through the variant III that maintains the EGFR signalling
pathway in a state of continuous activation. Binding of a growth
factor to its receptor initiates organised and oriented biochemical
intracellular events. These include the activation of the receptor, a
cascade of phosphorylation with different protein kinases and, at
the nuclear level, the activation of transcription factors. The effects
of EGFR activation on tumour cells are multiple and convergent,
thus favouring uncontrolled cell growth with an increase in cell
mobility and cell proliferation, a decrease in apoptotic machinery
and stimulation of angiogenesis. In the clinic, EGFR overexpres-
sion has been associated with chemoresistance, disease progres-
sion and poor survival (Baselga, 2002). Considering the set of
therapeutic tools targeting EGFR (Castillo et al, 2004), there are
two well-identified categories of drugs, with monoclonal anti-
bodies (mAbs) on one hand and tyrosine kinase inhibitors (TKIs)
on the other. Both treatment tools have reached a mature stage of
clinical development. Current therapeutic applications with anti-
EGFR drugs show encouraging clinical results. This is true mainly
for combinations with conventional cytotoxic agents. The rationale
of these combinations derives from preclinical studies where
additive and supra-additive interactions have been reported. In
agreement with Harari et al (2007), it can be considered that EGFR
signalling inhibition combined with radiation and chemotherapy
have opened promising perspectives. But a significant part of
patients in clinical trials do not demonstrate a favourable response.
The purpose of this review is to critically examine the experimental
conditions of the preclinical background for anti-EGFR drug—
cytotoxic combinations and to attempt to explain the gap between
clinical observations and preclinical data.
PHARMACOLOGICAL CONSEQUENCES OF EGFR
TARGETING
The outcome of EGFR targeting is characterised by the disruption
of a number of cellular processes that mirror the physiological
consequences of EGFR signal transduction at the level of cell
division, apoptosis and angiogenesis (Castillo et al, 2004). The
monoclonal antibody C225 (cetuximab) has been shown to slow
down cell division with changes in molecular actors controlling
cell-cycle checkpoints (Kiyota et al, 2002). Similar observations
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in addition to its ability to modulate mechanisms of drug
resistance, specifically the expression of ATP-binding cassette
(ABC) transport proteins mediated via the MDR1 gene (Smith
et al, 2008). It has been shown that both mAbs and TKIs are able to
modify the cellular levels in apoptosis-related proteins underlying
the pro-apoptotic effect of EGFR targeting (Ciardiello et al, 2000a;
Baselga, 2001). Similarly, a recent study has demonstrated that the
erlotinib-induced cell growth inhibition was accompanied by G1/S
phase arrest, predominantly by suppression of G1/S-related cyclins
and upregulation of the CDK inhibitor p27
KIP1 (Ling et al, 2007). A
negative influence of EGFR targeting on angiogenic biochemical
mediators has been shown for both mAbs and TKIs; for instance,
the tumour labelling in VEGF (vascular endothelial growth factor)
and factor VIII was reduced in xenograft models by C225 (Huang
and Harari, 2000) as well as by ZD1839 (Tortora et al, 2001).
Interestingly, and perhaps insufficiently emphasised, is the fact
that EGFR signal abrogation may lead to a diminution of key
mechanisms in DNA repair (Bandyopadhyay et al, 1998). In this
latter study, confocal imaging demonstrated that a significant
proportion of DNA protein kinase was colocalised with EGFR in
C225-EGFR targeted cells.
Logically, this above-mentioned pharmacological background
justified combining EGFR-targeting drugs with conventional
cytotoxic agents, in anticipation of supra-additive antitumour
effects. It must be underlined at this level that there is a marked
difference in the magnitude of antitumour effects in favour of
cytotoxic drugs as compared with EGFR-targeting agents.
EGFR TARGETING PLUS CONVENTIONAL
CYTOTOXIC AGENTS
From the bench
On the basis of current knowledge, there is no apparent distinction
between TKIs and mAbs regarding their propensity to trigger, in
the majority of cases, synergistic cytotoxic interactions with
chemotherapeutic agents or irradiation. To a great extent this
synergy can be attributed to the well-identified impact of EGFR-
targeting drugs on cell division, apoptosis, angiogenesis and DNA
repair (see above). In addition, the occurrence of cross-resistance
is infrequent as the cellular targets and mechanisms of action of
cytotoxic drugs and EGFR-targeting therapeutics are different. It
must be stressed, however, that there are few, if any, experimental
studies designed to thoroughly explore the different anticancer
agents, class by class, in association with EGFR-targeting drugs
and using appropriate methods of analysis (the Chou and Talalay
model, for instance). An exception is the study by Ciardiello et al
(2000b), who undertook to combine ZD1839 (gefitinib) and a panel
of anticancer agents including platinum derivatives, taxanes,
doxorubicin, etoposide, topotecan and raltitrexed. Treatments
combining cytotoxic drugs and ZD1839 produced tumour growth
arrests in established GEO human colon cancer xenografts,
whereas, in single-agent-treated mice, tumours resumed growth
similar to controls. On comparable experimental bases, Sirotnak
et al (2000) reached similar conclusions when combining ZD1839
and taxanes, whereas associations with gemcitabine or vinorelbine
led to more contrasting results. When combining gemcitabine and
PKI 166, Kedar et al (2002) found convincing evidence of supra-
additivity in human renal cell carcinoma growing orthotopically in
nude mice. We reported on the association between ZD1839 and
cisplatin-5-fluorouracil (5-FU) in head and neck cancer cell lines,
which demonstrated the presence of sequence-dependent syner-
gistic cytotoxic effects (Magne ´ et al, 2002). Synergistic interaction
between cisplatin and TKIs was also observed with CI-1033, an
irreversible pan ErbB TKI (Gieseg et al, 2001). Erlotinib, combined
with chemotherapy, has also been studied in preclinical models of
lung, pancreas, and head and neck cancer. When administered in
combination with cisplatin and gemcitabine, erlotinib more
effectively induced xenograft growth arrest, and this combination
was more effective than either the chemotherapeutic agents or
erlotinib alone (Higgins et al, 2004). Similar observations were
previously reported regarding experimental chemosensitisation by
EGFR blockade using mAbs, particularly C225. Thus, C225 (or
M225) has been shown to enhance the antitumour activity of
several anticancer agents in both cell cultures and human tumour
xenograft models (Magne ´ et al, 2002; Prewett et al, 2002;
Balin-Gauthier et al, 2005). Of note, the results reported by
Prewett et al (2002) demonstrated not only enhanced antitumour
activity of C225 combined with irinotecan (CPT-11), but also that
this combination was highly effective against established, CPT-11-
refractory colorectal tumours. A majority of combinations between
anti-EGFR drugs and cytotoxic agents result in additive and supra-
additive cytotoxic effects. However, it cannot be ruled out that
antagonisms may also occur with drugs not covered by these
experiments.
To the bedside
In a number of cases, preclinical studies on EGFR targeting
combined with cytotoxic drugs have been confirmed clinically, the
most convincing instance being the therapeutic success achieved
by the cetuximab–irinotecan association in irinotecan-refractory
advanced colorectal cancer patients (Cunningham et al, 2004). In
head and neck cancer, encouraging results have been obtained
recently with the association between cisplatin and cetuximab in
cisplatin-refractory patients (Baselga et al, 2005) and also,
importantly, with a combination of cetuximab and irradiation
(Bonner et al, 2006). Although the EGFR target is present in the
most frequent cancers, such as breast and prostate tumours, the
benefits of anti-EGFR therapy plus cytotoxic agents are not yet
apparent in these cases. More precisely, few clinical data confirm a
superior clinical activity when associating anti-EGFR TKIs with
cytotoxic agents. This contrasts with convincing clinical data on
the benefit of combining mAbs like cetuximab with cytotoxic
agents. A ray of hope comes from the erlotinib–gemcitabine
combination in advanced pancreatic cancer but the benefit in
terms of increased survival remains very modest in comparison
with gemcitabine alone (Moore, 2005). Particularly demonstrative
was the failure of the TKI–chemotherapy combinations in
pretreated lung cancer patients, which was true for both gefitinib
and erlotinib (Gatzemeier et al, 2004; Herbst et al, 2005). In this
context, how can the discrepancies between the promising bench
data and the disappointing bedside observations be explained?
Apart from the classical arguments based on the obvious
difficulties involved in extrapolating from experimental studies
on tumour cell lines to the clinical reality; here, we will be dealing
with the adequacy of the applied models and the treatment of data
from preclinical experiments. We will also examine the importance
of the sequence of drug combinations involving anti-EGFR drugs
and cytotoxic agents.
Back to the bench: models and limitations
To evaluate quantitatively the results of drug combinations, Chou
and Talalay (1984) have proposed a method of calculation based
on kinetic principles. The approach is simple and applicable
whatever the dose–effect relationships (hyperbolic or sigmoidal),
whatever the effects of the drugs (agonists or antagonists, mutually
exclusive or not) and whatever the number of drugs involved in the
combination (two or three). Many of the preclinical in vitro studies
analysing the effects of combining EGFR-targeting drugs and
chemotherapeutic compounds have been performed using the
Chou and Talalay method. However, application of this method to
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significance of their final conclusion. This is mainly because,
unlike true cytotoxic dose–response curves, cell proliferation
inhibition leads to incomplete dose–effect curves (that is,
total growth inhibition cannot be achieved) with IC50 values
(defined as the drug concentration at the inflexion point) in
the mM range. These concentrations are well above the pharma-
cologically relevant concentrations, reflecting a partial dependency
of tumour cell lines to EGFR signalling. Only very rare EGF-
addicted cell lines, such as A431, with a particularly high EGFR
expression can give a complete dose–effect curve with an anti-
EGFR drug. Of note, the Chou and Talalay model is also not
applicable for the examination of tumour growth in vivo,i n
immunodeficient mice for instance. Thus, a number of in vivo
studies testing combinations between anti-EGFR drugs and
chemotherapeutic agents have concluded that synergistic interac-
tions have occurred without the application of a specific statistical
tool to calculate the final combined effects. In experiments
combining cetuximab and irinotecan, Prewett et al (2002) have
proposed the notion of a combination ratio (CR) between expected
and observed FTV, FTV being the fractional tumour volume
calculated as the ratio between the mean tumour volumes of treated
and untreated tumours. This simple approach has the advantage of
distinguishing supra- from infra-additivity but was not used by
Prewett as a strict statistical evaluation. In this respect, comparisons
of Kaplan–Meier curves as used for survival analyses in patients
should be encouraged; these curves could compare the times
necessary for individual tumours to reach predefined volumes, and
this approach would allow statistical comparisons between groups
but not a strict evaluation of synergistic interactions.
Another limitation of in vivo combination studies is the fact
that conclusions are often drawn from one or two xenograft
models with a fixed schedule. A convincing illustration is
provided by the paclitaxel–gefitinib combination re-examined by
Solit et al (2005) regarding the importance of the drug association
schedule. These authors made the logical hypothesis that
gefitinib leading to G1 growth arrest of EGFR-dependent tumour
cells may, following continuous administration, attenuate the
effects of tubulin inhibitors – such as paclitaxel – which act
primarily during mitosis. From gefitinib–paclitaxel combination
studies on tumour xenograft models, they found that, in
contrast to continuous administration of gefitinib, 2 days of
gefitinib before paclitaxel was a most effective treatment giving
significantly greater tumour regression and more frequent
complete responses than the other schedule. Onn et al (2004)
who used an orthotopic model of lung cancer provided further
confirmation of an unfavourable schedule of association between
continuous exposure to an EGFR TKI and paclitaxel. Three in vivo
experiments showed a schedule-dependent efficacy of gefitinib
with a better efficacy when gefitinib was administered after the
cytotoxic agent, that is, in combination with cisplatin on a murine
hepatocellular carcinoma (Zhu et al, 2005), or with gemcitabine on
a head and neck carcinoma xenograft (Chun et al, 2006) or with
docetaxel on a bladder carcinoma xenograft (Kassouf et al, 2006).
Sequential administration of gefitinib given after chemotherapy
seems to be preferable than concomitant treatment. It is thus
possible that part of the failure of the gefitinib–chemotherapy
combination in patients with nonsmall cell lung cancer (NSCLC)
may be accounted for by an inadequate schedule of association
between the anti-EGFR drug and cytotoxic agents. Reports by
others (Xu et al, 2003a; Morelli et al, 2005) and ourselves (Magne ´
et al, 2002) have clearly underlined, from in vitro studies, the
importance of the sequence of association for the final anti-
proliferative effect of cytotoxic drugs combined with EGFR
inhibitors. Thus, synergy is not always the rule and some
antagonistic effects may result from inappropriate sequences
between anti-EGFR drugs and cytotoxic agents as recently stressed
by Davies et al (2006).
A RAY OF HOPE
Recent experimental data indicate that gefitinib can restore
sensitivity to topotecan in multidrug-resistant NSCLC cells over-
expressing the breast cancer resistance protein (BCRP)
(Nagashima et al, 2006). This observation is consistent with a
previous report pointing out that certain TKIs, including gefitinib,
interact with ABC multidrug transporter proteins with high affinity
(Ozvegy-Laczka et al, 2004). In cells expressing ABCG2, gefitinib
greatly increased the cytotoxicity of mitoxantrone. Recently, Yang
et al (2005) showed that sensitivity to chemotherapeutic agents
(paclitaxel, topotecan and doxorubicin) of multidrug resistant
(MDR) cancer cells was increased in the presence of clinically
relevant concentrations of gefitinib. Drug pharmacokinetics that is
affected by BCRP or P-glycoprotein may be altered in the presence
of gefitinib. In nontumour-bearing mice, gefitinib treatment
dramatically increased the bioavailability of irinotecan after
simultaneous oral administration (Stewart et al, 2004). Van
Schaeybroeck et al (2005) showed that phospho-EGFR levels
determine the sensitivity of human colorectal cancer cells to
gefitinib alone and that chemotherapy-mediated changes in
phospho-EGFR levels determine the nature of interaction between
gefitinib and chemotherapy. A significant antagonism was
observed between gefitinib- and oxaliplatin-induced cell death in
cell lines with low basal EGFR phosphorylation levels, whereas in
cell lines with high basal EGFR phosphorylation, the interaction
between gefitinib and oxaliplatin was additive and often supra-
additive/synergistic (Van Schaeybroeck et al, 2005). Similar results
were obtained in human NSCLC cells (Van Schaeybroeck et al,
2006). However, different data were obtained for cetuximab
preclinical antitumour activity (monotherapy and combination
based), which was not predicted by relative total or activated EGFR
tumour expression levels (Wild et al, 2006). A major advance for a
patient selection with the objective to draw greater benefits from a
combination between anti-EGFR drugs and conventional chemo-
therapeutic agents comes from the tumour determination of
EGFR and K-Ras mutational status. In lung cancer patients,
molecular studies have revealed that EGFR-activating mutations
are frequently found in patients who have the best outcomes with
EGFR TKIs combined with conventional chemotherapy (Bonomi
et al, 2007). Several groups from Europe and the United States
have reported that the absence of K-Ras mutation was a condition
necessary to obtain a clinical response to the association between
cetuximab and irinotecan in irinotecan refractory patients
(Lie `vre et al, 2008).
Another interesting perspective is the combination of anti-EGFR
drugs with other targeted agents and cytotoxic treatments. We,
thus, recently investigated the effects of a combination of AZD2171
– a highly potent, orally active, VEGF-signalling inhibitor –
gefitinib and irradiation (Bozec et al, 2007). The antitumour
efficacy of these treatments, administered alone or in combination,
was assessed in a human head and neck tumour cell line, CAL33,
established as xenografts in nude mice. Greater inhibition of
tumour growth was seen with the triple combination that almost
completely abolished tumour cell proliferation. Of interest, the
marked irradiation-induced enhancement of the DNA-repair
enzyme ERCC1 expression was totally abolished by the triple
combination.
CONCLUSION
Epidermal growth factor receptor-targeting agents, with their
encouraging efficacy, mild toxicity profile and quality of life
benefits, offer hope for patients with advanced cancer. Despite the
failure of combining TKIs with chemotherapy in several large
phase III clinical trials (especially in stage III NSCLC), the
chemotherapy and targeted therapy combination approach is still
EGFR-targeting drugs plus cytotoxic agents
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efforts will have to be directed at identifying more efficient and
effective ways of differentiating the EGFR-targeting drugs from
each other, integrating these agents with conventional treatments,
and finding better ways of predicting whether prolongation of life
for an individual patient will be achieved.
Preclinical sequencing data are encouraging and will
hopefully translate to the clinical setting. Appropriately
designed clinical trials are required to define the optimum dose,
schedule and sequence for these agents in combination with
conventional therapies. Several clinical studies are ongoing
or planned to examine sequential dosing regimens of erlotinib
or gefitinib with chemotherapy in patients with various solid
tumour types. The sequential approach will be tested in a US
intergroup phase III study in which patients will be randomly
assigned to gefitinib or placebo following chemoradiotherapy and
consolidation docetaxel in patients with inoperable stage III
NSCLC.
Further translational studies including examination of molecu-
lar biomarkers such as gene-expression profiling, will help us to
identify critical markers and allow us to select the patients most
likely to benefit from therapy with TKIs. The complexity of the
ErbB signalling network and the significance of various activated
downstream markers remain under intense investigation with
regard to potential prognostic and predictive value.
The next clinical studies with EGFR-targeting agents should be
designed with a strong translational research component to
address several key questions, such as which patients are most
likely to have a therapeutic benefit, what are the potential
predictive factors of response or resistance to these agents
and what are the best strategies for their combination with
conventional and/or other targeted anticancer treatments.
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